Total submissions: 7
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Counsyl | RCV000169241 | SCV000220515 | likely pathogenic | Hereditary factor XI deficiency disease | 2014-07-16 | criteria provided, single submitter | literature only | |
Fulgent Genetics, |
RCV000169241 | SCV000893677 | pathogenic | Hereditary factor XI deficiency disease | 2018-10-31 | criteria provided, single submitter | clinical testing | |
NIHR Bioresource Rare Diseases, |
RCV000851708 | SCV000899526 | pathogenic | Abnormal bleeding | 2019-02-01 | criteria provided, single submitter | research | |
Labcorp Genetics |
RCV001247722 | SCV001421162 | pathogenic | not provided | 2024-02-04 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Trp519*) in the F11 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in F11 are known to be pathogenic (PMID: 23929304). This variant is present in population databases (rs201007090, gnomAD 0.03%). This premature translational stop signal has been observed in individual(s) with factor XI deficiency (PMID: 11122101, 20015217). This variant is also known as p.501*. ClinVar contains an entry for this variant (Variation ID: 188887). For these reasons, this variant has been classified as Pathogenic. |
ISTH- |
RCV000169241 | SCV004013066 | pathogenic | Hereditary factor XI deficiency disease | criteria provided, single submitter | clinical testing | ||
Mayo Clinic Laboratories, |
RCV001247722 | SCV005413680 | pathogenic | not provided | 2024-05-09 | criteria provided, single submitter | clinical testing | PP5, PM1_supporting, PM2_moderate, PM3_very_strong, PS4_moderate, PVS1 |
Natera, |
RCV001835701 | SCV002082952 | pathogenic | Plasma factor XI deficiency | 2020-03-20 | no assertion criteria provided | clinical testing |